London, United Kingdom 2013 Poster Session Blue Cerebrovasc Dis 2013; 35 (suppl 3)1-854 619 517 Epidemiology of stroke Variation within the HDAC9 gene shows association with the ischemic stroke subtype of large vessel disease in a Swedish population H. Lövkvist1, C. Jern2, K. Jood3, A. Lindgren4, B. Norrving5 Lund University, Department of Clinical Sciences, Lund, Skåne University Hospital, Swe-den, Lund, SWEDEN1, The Sahlgrenska Academy at University of Gothenburg, Institute of Neu-roscience and Physiology, Department of Clinical Neuroscience and Rehabilitation,, Gothenburg, SWEDEN2, The Sahlgrenska Academy at University of Gothenburg, Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation,, Gothenburg, SWEDEN3, Lund University, Department of Clinical Sciences, Lund, Skåne University Hospital, Sweden, Lund, SWEDEN4, Lund University, Department of Clinical Sciences, Lund, Skåne University Hospital, Sweden, Lund, SWEDEN5 Background: In a previous GWAS linked to the International Stroke Genetics Consortium (ISGC) and the Wellcome Trust Case Control Consortium 2 (WTCCC2), the SNP rs11984041 within the histone deacetylase 9 (HDAC9) gene was found to be significantly associated with large vessel disease (LVD). This finding was replicated (by examining proxy SNP rs2107595) in a meta-analysis within the METASTROKE collaboration project. Methods: SNP rs11984041 on chromosome 7p21.1, genotyped at KBioscience, UK, using IPLEX on a Mas-sARRAY platform (Sequenom), was examined. A sample of 2902 IS cases and 1842 control subjects from three geographic areas in South Sweden was assessed. The TOAST subtypes LVD, small ves-sel disease (SVD), cardioembolism (CE) and cryptogenic stroke were furthermore investigated for two of these areas (each subtype with a sample size of 207-556 cases, 1114 controls). Crude ORs as well as ORs obtained through multiple logistic regression (MLR) were estimated. Results: SNP rs11984041 showed a significant association with LVD (OR=1.60; 95% CI: 1.16-2.21; P=0.004), but not with IS in general (OR=1.14; 95% CI: 0.99-1.31; P=0.079). MLR controlling for diabetes mellitus, hypertension and current smoking provided similar or not distinctly stronger as-sociations (for LVD: OR=1.78; 95% CI: 1.22-2.57; P=0.002, for IS: OR=1.14; 95% CI: 0.98-1.33; P=0.091). Conclusion: Our results support previous findings of an association between variations within HDAC9 on chro-mosome 7p21.1 and the stroke subtype of LVD. 518 Epidemiology of stroke Effects of clinical and laboratory variables at admission and of in-hospital treatment with cardiovascular drugs on short term prognosis of ischemic stroke. The GIFA study A. Tuttolomondo1, D. Di Raimondo2, C. Pedone3, A. Pinto4, G. Licata5 Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo ( Italy), Palermo, ITALY1, Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Italy, Palermo, 2, Cattedra di Geriatria e Gerontologia, Campus Biomedico Roma, Italy, Roma, ITALY3, Dipartimento Biomedico di Medicina Interna e Specialistica, Univer-sità degli Studi di Palermo, Italy, Palermo, ITALY4, Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo, Italy, Palermo, ITALY5 Background: No information exists, to our knowledge, about the possible role of cardiovascular drug administration in the acute phase of ischemic stroke and possible effects on stroke outcome. The aim of our study was to evaluate the relationship between in-hospital treatment with cardiovas-cular drugs in patients with acute ischemic stroke and some outcome indicators . Methods: 1096 subjects enrolled in the GIFA study, who had a main discharge diagnosis of ischemic stroke represent the final sample. Drugs considered for the analysis were the following: ACE-inhib-itors (ACE-I), angiotensin II receptor blockers (ARBs), statins, calcium-channel-blockers (CCBs), antiplatelet (APL) drugs, antivitamin-k (VKAs), and heparins. As outcome indicators we choose in-hospital mortality, cognitive function evaluated by Hodkinson Abbreviated Mental Test (HAMT), and functional status evaluated by activity daily living (ADL). Indicators of a good outcome were: no in-hospital mortality, HAMT > 6 and 0 ADL impaired. Results: Patients with a good outcome showed a higher rate of in-hospital treatment with ACE-in-hibitors, calcium-channel blockers and a lower rate of pre-treatment with heparin. Conclusions : Our study suggests that if a patient with acute ischemic stroke has higher SBP at admission, higher total cholesterol plasma levels, a lower Charlson index and if is treated with ACE-inhibitors, calcium channel blockers and antiplatelet drugs the short term outcome is better in terms of in-hospital mortality and functional indicators such as cognitive and functional perfor-mance at discharge.
Karger_ESC London_2013
To see the actual publication please follow the link above